サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：骨髄異形成症候群（MDS）治療の世界市場規模：治療タイプ・エンドユーザー・地域別の予測（2022年～2028年）
市場調査レポート
商品コード
1090024

骨髄異形成症候群（MDS）治療の世界市場規模：治療タイプ・エンドユーザー・地域別の予測（2022年～2028年）

Global Myelodysplastic Syndrome Treatment Market Size study, by Treatment Type, by End-User and Regional Forecasts 2022-2028
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
骨髄異形成症候群（MDS）治療の世界市場規模：治療タイプ・エンドユーザー・地域別の予測（2022年～2028年）
出版日: 2022年06月07日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の骨髄異形成症候群（MDS）治療市場では、新薬開発のための研究開発費の増加や社会的認知度の向上により、予測期間中に採用が進むと予測されています。

また、標的療法を提供するための政府による取り組みや魅力的な償還政策が、予測期間中の市場成長を高めると思われます。しかし、薬による副作用が、予測期間である2022年～2028年の市場成長を阻害する可能性があります。

当レポートでは、世界の骨髄異形成症候群（MDS）治療市場を調査し、市場の概要、業界分析、COVID-19によるリスク評価、治療タイプ・エンドユーザー・地域別の分析、および競合情報などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の骨髄異形成症候群（MDS）治療市場：定義と範囲

第3章 世界の骨髄異形成症候群（MDS）治療市場：市場力学

  • 骨髄異形成症候群（MDS）治療市場：影響分析（2020年～2028年）

第4章 世界の骨髄異形成症候群（MDS）治療市場：業界分析

  • ポーターのファイブフォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの推奨事項と結論
  • 主要な投資機会
  • 主要な成功戦略

第5章 リスク評価：COVID-19の影響

    • 業界に対するCOVID-19の全体的影響の評価
    • COVID-19以前・以後の市場シナリオ

第6章 世界の骨髄異形成症候群（MDS）治療市場：治療タイプ別

  • 市場スナップショット
  • 実績 - 潜在的な分析
  • 推定・予測（2018年～2028年）
  • サブセグメント分析
    • 化学療法
    • 免疫療法
    • 幹細胞移植
    • その他の治療タイプ

第7章 世界の骨髄異形成症候群（MDS）治療市場：エンドユーザー別

  • 市場スナップショット
  • 実績 - 潜在的な分析
  • 推定・予測（2018年～2028年）
  • サブセグメント分析
    • 病院
    • 専門クリニック
    • その他のエンドユーザー

第8章 世界の骨髄異形成症候群（MDS）治療市場：地域別分析

  • 地域別市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • その他の地域

第9章 競合情報

  • 主要市場戦略
  • 企業プロファイル
    • AbbVie Inc.
    • Accord Healthcare
    • Bristol-Myers Squibb
    • Jazz Pharmaceuticals Inc
    • Novartis AG
    • Lupin Pharmaceuticals
    • Otsuka America Pharmaceutical Inc.
    • Onconova Therapeutics
    • Takeda Pharmaceutical Company Limited
    • Astex Pharmaceuticals, Inc.

第10章 調査プロセス

図表

LIST OF TABLES

  • TABLE 1. Global Myelodysplastic Syndrome (MDS) Treatment Market, report scope
  • TABLE 2. Global Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by Region 2018-2028 (USD Billion)
  • TABLE 3. Global Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by Treatment Type 2018-2028 (USD Billion)
  • TABLE 4. Global Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by End-User 2018-2028 (USD Billion)
  • TABLE 5. Global Myelodysplastic Syndrome (MDS) Treatment Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 6. Global Myelodysplastic Syndrome (MDS) Treatment Market by region, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 7. Global Myelodysplastic Syndrome (MDS) Treatment Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 8. Global Myelodysplastic Syndrome (MDS) Treatment Market by region, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 9. Global Myelodysplastic Syndrome (MDS) Treatment Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 10. Global Myelodysplastic Syndrome (MDS) Treatment Market by region, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 11. Global Myelodysplastic Syndrome (MDS) Treatment Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 12. Global Myelodysplastic Syndrome (MDS) Treatment Market by region, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 13. Global Myelodysplastic Syndrome (MDS) Treatment Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 14. Global Myelodysplastic Syndrome (MDS) Treatment Market by region, estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 15. U.S. Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 16. U.S. Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 17. U.S. Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 18. Canada Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 19. Canada Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 20. Canada Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 21. UK Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 22. UK Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 23. UK Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 24. Germany Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 25. Germany Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 26. Germany Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 27. RoE Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 28. RoE Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 29. RoE Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 30. China Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 31. China Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 32. China Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 33. India Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 34. India Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 35. India Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 36. Japan Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 37. Japan Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 38. Japan Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 39. RoAPAC Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 40. RoAPAC Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 41. RoAPAC Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 42. Brazil Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 43. Brazil Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 44. Brazil Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 45. Mexico Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 46. Mexico Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 47. Mexico Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 48. RoLA Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 49. RoLA Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 50. RoLA Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 51. Row Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts, 2018-2028 (USD Billion)
  • TABLE 52. Row Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 53. Row Myelodysplastic Syndrome (MDS) Treatment Market estimates & forecasts by segment 2018-2028 (USD Billion)
  • TABLE 54. List of secondary sources, used in the study of Global Myelodysplastic Syndrome (MDS) Treatment Market
  • TABLE 55. List of primary sources, used in the study of Global Myelodysplastic Syndrome (MDS) Treatment Market
  • TABLE 56. Years considered for the study
  • TABLE 57. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Myelodysplastic Syndrome (MDS) Treatment Market, research methodology
  • FIG 2. Global Myelodysplastic Syndrome (MDS) Treatment Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Myelodysplastic Syndrome (MDS) Treatment Market, key trends 2021
  • FIG 5. Global Myelodysplastic Syndrome (MDS) Treatment Market, growth prospects 2022-2028
  • FIG 6. Global Myelodysplastic Syndrome (MDS) Treatment Market, porters 5 force model
  • FIG 7. Global Myelodysplastic Syndrome (MDS) Treatment Market, pest analysis
  • FIG 8. Global Myelodysplastic Syndrome (MDS) Treatment Market, value chain analysis
  • FIG 9. Global Myelodysplastic Syndrome (MDS) Treatment Market by segment, 2018 & 2028 (USD Billion)
  • FIG 10. Global Myelodysplastic Syndrome (MDS) Treatment Market by segment, 2018 & 2028 (USD Billion)
  • FIG 11. Global Myelodysplastic Syndrome (MDS) Treatment Market by segment, 2018 & 2028 (USD Billion)
  • FIG 12. Global Myelodysplastic Syndrome (MDS) Treatment Market by segment, 2018 & 2028 (USD Billion)
  • FIG 13. Global Myelodysplastic Syndrome (MDS) Treatment Market by segment, 2018 & 2028 (USD Billion)
  • FIG 14. Global Myelodysplastic Syndrome (MDS) Treatment Market, regional snapshot 2018 & 2028
  • FIG 15. North America Myelodysplastic Syndrome (MDS) Treatment Market 2018 & 2028 (USD Billion)
  • FIG 16. Europe Myelodysplastic Syndrome (MDS) Treatment Market 2018 & 2028 (USD Billion)
  • FIG 17. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Market 2018 & 2028 (USD Billion)
  • FIG 18. Latin America Myelodysplastic Syndrome (MDS) Treatment Market 2018 & 2028 (USD Billion)
  • FIG 19. Global Myelodysplastic Syndrome (MDS) Treatment Market, company Market share analysis (2021)
目次

Global Myelodysplastic Syndrome (MDS) Treatment Market is valued at approximately USD XXXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Myelodysplastic Syndrome (MDS) Treatment is a term used to describe a category of bone marrow disorders in which the bone marrow fails to create enough healthy blood cells. MDS is also known as "bone marrow failure condition". Ineffective hematopoiesis, as well as anomalies in proliferation, differentiation, and apoptosis, characterise these illnesses. The increased R&D spending on new drug development and increasing public awareness have led to the adoption of Myelodysplastic Syndrome (MDS) Treatment across the forecast period. For Instance: as per Cancer.Net in 2022, every year, about 10,000 people in the United States are diagnosed with MDS. MDS is rare in adults under the age of 50. People in their 70s are the most likely to develop it. The number of people diagnosed with MDS each year is projected to rise as the US population continues to age. As per Congressional Budget Office 2021, the pharmaceutical sector spent $83 billion on research and development in 2019. Inflation-adjusted, that sum is around ten times what the industry spent every year in the 1980s. Also, some initiatives by the government to provide targeted therapies and attractive reimbursement policies are likely to increase the market growth during the forecast period. However, adverse effects caused by the medicine may impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the Global Myelodysplastic Syndrome (MDS) Treatment market study include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of market share owing to increased R&D spending on new drug development and increasing public awareness. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2022-2028. Factors such as initiatives by the government to provide targeted therapies and attractive reimbursement policies would create lucrative growth prospects for the Myelodysplastic Syndrome (MDS) Treatment market across Asia-Pacific region.

Major market players included in this report are:

AbbVie Inc.

Accord Healthcare

Bristol-Myers Squibb

Jazz Pharmaceuticals Inc

Novartis AG

Lupin Pharmaceuticals

Otsuka America Pharmaceutical Inc.

Onconova Therapeutics

Takeda Pharmaceutical Company Limited

Astex Pharmaceuticals, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment:

Chemotherapy,

Immune Treatments

Stem Cell Transplant

Other Treatment Types

By End-User:

Hospitals

Specialty Clinics

Other End-Users

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Myelodysplastic Syndrome (MDS) Treatment Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Billion)
    • 1.2.1. Myelodysplastic Syndrome (MDS) Treatment Market, by Region, 2020-2028 (USD Billion)
    • 1.2.2. Myelodysplastic Syndrome (MDS) Treatment Market, by Treatment Type, 2020-2028 (USD Billion)
    • 1.2.3. Myelodysplastic Syndrome (MDS) Treatment Market, by End-User, 2020-2028 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Myelodysplastic Syndrome (MDS) Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Myelodysplastic Syndrome (MDS) Treatment Market Dynamics

  • 3.1. Myelodysplastic Syndrome (MDS) Treatment Market Impact Analysis (2020-2028)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increased R&D spending on new drug development
      • 3.1.1.2. Increasing public awareness
    • 3.1.2. Market Challenges
      • 3.1.2.1. Adverse effects caused by the medicine
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Initiatives by the government to provide targeted therapies and attractive reimbursement policies

Chapter 4. Global Myelodysplastic Syndrome (MDS) Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion
  • 4.5. Top investment opportunity
  • 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

    • 5.1.1. Assessment of the overall impact of COVID-19 on the industry
    • 5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Myelodysplastic Syndrome (MDS) Treatment Market, by Treatment Type

  • 6.1. Market Snapshot
  • 6.2. Global Myelodysplastic Syndrome (MDS) Treatment Market by Treatment Type, Performance - Potential Analysis
  • 6.3. Global Myelodysplastic Syndrome (MDS) Treatment Market Estimates & Forecasts by Treatment Type, 2018-2028 (USD Billion)
  • 6.4. Myelodysplastic Syndrome (MDS) Treatment Market, Sub Segment Analysis
    • 6.4.1. Chemotherapy
    • 6.4.2. Immune Treatments
    • 6.4.3. Stem Cell Transplant
    • 6.4.4. Other Treatment Types

Chapter 7. Global Myelodysplastic Syndrome (MDS) Treatment Market, by End-User

  • 7.1. Market Snapshot
  • 7.2. Global Myelodysplastic Syndrome (MDS) Treatment Market by End-User, Performance - Potential Analysis
  • 7.3. Global Myelodysplastic Syndrome (MDS) Treatment Market Estimates & Forecasts by End-User, 2018-2028 (USD Billion)
  • 7.4. Myelodysplastic Syndrome (MDS) Treatment Market, Sub Segment Analysis
    • 7.4.1. Hospitals
    • 7.4.2. Specialty Clinics
    • 7.4.3. Other End-Users

Chapter 8. Global Myelodysplastic Syndrome (MDS) Treatment Market, Regional Analysis

  • 8.1. Myelodysplastic Syndrome (MDS) Treatment Market, Regional Market Snapshot
  • 8.2. North America Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.2.1. U.S. Myelodysplastic Syndrome (MDS) Treatment Market
      • 8.2.1.1. Treatment Type breakdown estimates & forecasts, 2018-2028
      • 8.2.1.2. End-User breakdown estimates & forecasts, 2018-2028
    • 8.2.2. Canada Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.3. Europe Myelodysplastic Syndrome (MDS) Treatment Market Snapshot
    • 8.3.1. U.K. Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.3.2. Germany Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.3.3. France Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.3.4. Spain Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.3.5. Italy Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.3.6. Rest of Europe Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.4. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Snapshot
    • 8.4.1. China Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.4.2. India Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.4.3. Japan Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.4.4. Australia Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.4.5. South Korea Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.4.6. Rest of Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.5. Latin America Myelodysplastic Syndrome (MDS) Treatment Market Snapshot
    • 8.5.1. Brazil Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.5.2. Mexico Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.6. Rest of The World Myelodysplastic Syndrome (MDS) Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. AbbVie Inc.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Accord Healthcare
    • 9.2.3. Bristol-Myers Squibb
    • 9.2.4. Jazz Pharmaceuticals Inc
    • 9.2.5. Novartis AG
    • 9.2.6. Lupin Pharmaceuticals
    • 9.2.7. Otsuka America Pharmaceutical Inc.
    • 9.2.8. Onconova Therapeutics
    • 9.2.9. Takeda Pharmaceutical Company Limited
    • 9.2.10. Astex Pharmaceuticals, Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption